Shubh Goel Net Worth

Shubh Goel biography

Shubh Goel serves as Chief Commercial Officer of the Company. Ms. Goel has been employed by us since September 2019. Ms. Goel is a proven leader with nearly 20 years of global commercial experience successfully building and executing the launch of several oncology products. Most recently, she served as Vice President of Commercial Strategy and Operations at Odonate Therapeutics, Inc. Prior to Odonate, Ms. Goel previously served in multiple leadership positions at Celgene Corporation, including serving as Executive Director, Global Early Commercialization and previously as Head of U.S. Marketing, Oncology. While at Celgene, she oversaw the successful execution of the U.S. launch of Abraxane® in pancreatic cancer and had overall responsibility for marketing the U.S. solid tumor franchise. Ms. Goel received a B.Sc. degree in biochemistry from the University of Bath.

What is the salary of Shubh Goel?

As the Chief Commercial Officer of Fennec Pharmaceuticals Inc, the total compensation of Shubh Goel at Fennec Pharmaceuticals Inc is $1,029,540. There are 1 executives at Fennec Pharmaceuticals Inc getting paid more, with Rostislav Raykov having the highest compensation of $1,477,140.

How old is Shubh Goel?

Shubh Goel is 46, she's been the Chief Commercial Officer of Fennec Pharmaceuticals Inc since 2019. There are 6 older and 2 younger executives at Fennec Pharmaceuticals Inc. The oldest executive at Fennec Pharmaceuticals Inc is Anne McKay, 67, who is the Regulatory Consultant.

What's Shubh Goel's mailing address?

Shubh's mailing address filed with the SEC is 68 TW ALEXANDER DRIVE, PO BOX 13628, , DURHAM, NC, 27709.

Insiders trading at Fennec Pharmaceuticals Inc

Over the last 10 years, insiders at Fennec Pharmaceuticals Inc have traded over $13,607,192 worth of Fennec Pharmaceuticals Inc stock and bought 1,966,488 units worth $9,890,813 . The most active insiders traders include Management Pr, Llcmancheste..., Spacavazza Paolo Cavazza En..., and Rosty Raykov. On average, Fennec Pharmaceuticals Inc executives and independent directors trade stock every 69 days with the average trade being worth of $442,734. The most recent stock trade was executed by Rosty Raykov on 31 August 2024, trading 2,431 units of FENC stock currently worth $13,419.

What does Fennec Pharmaceuticals Inc do?

fennec pharmaceuticals inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the united states. its lead product pedmark, a formulation of sodium thiosulfate, which has completed the phase iii clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. the company was formerly known as adherex technologies inc. and changed its name to fennec pharmaceuticals inc. in september 2014. fennec pharmaceuticals inc. was founded in 1996 and is based in research triangle park, north carolina.

Fennec Pharmaceuticals Inc executives and stock owners

Fennec Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Rostislav Raykov,
  Chief Executive Officer, Director
• Shubh Goel,
  Chief Commercial Officer
• Robert Andrade,
  Chief Financial Officer
• Rostislav Raykov,
  CEO & Director
• Shubh Goel,
  Chief Commercial Officer
• Robert C. Andrade,
  Chief Financial Officer
• Khalid Islam,
  Independent Chairman of the Board
• Chris Rallis,
  Independent Director
• Adrian Haigh,
  Independent Director
• Marco Brughera,
  Independent Director
• Jodi Cook,
  Independent Director
• Alexander D. Smith M.S.,
  Consultant
• Anne McKay,
  Regulatory Consultant
• Lei Fang,
  Pres of Pharstat Inc
• Mark Gowland,
  Controller
• Management Pr, Llcmancheste...,
  
• Management Co Llc Mancheste...,
  
• Spacavazza Paolo Cavazza En...,
  
• Capital Advisors Lp Southpo...,
  
• Jeffrey S. Hackman,
  Chief Executive Officer
• Rosty Raykov,